Read more about Strides dips 6% from high on profit booking as Aditya Puri joins as advisor on Business Standard. In the past six months, the stock has zoomed 130 per cent, as compared to 33 per cent rally in the S&P BSE Sensex
Strides Pharma may get transferred to a clutch of investors as promoters plan to exit
December 30, 2020
Company’s vaccine facility likely to go on stream in January
Strides Pharma Science Limited, with no successors to take the company forward, is at crossroads as promoters are planning to exit. With their plan to exit the company, it is learnt that the company may get transferred to a clutch of investors.
“The company is expected to be transferred to a clutch of investors as the promoters are looking to exit for personal reasons,” said a veteran pharma specialist, who did not want to be identified.
D-St investors richer by Rs 1.5 lakh crore as Sensex wipes off Monday s loss
SECTIONS
Share
Synopsis
Investors grew richer by Rs 1.51 lakh crore as the total market cap of BSE-listed companies rose to Rs 185.18 lakh crore.
Getty Images
The 30-share pack Sensex climbed 529.36 points, or 1.14 per cent, to 46,973.54. Its broader peer, NSE Nifty added 148.15 points, or 1.09 per cent, to 13,749.25.
NEW DELHI: Reliance Industries and banking stocks saw enough demand on Thursday to extend gains in benchmark indices to the third straight day, lifting them to near record highs.
Three straight days of gains ahead of Christmas holidays has helped Sensex wipe off all losses incurred in Monday s market crash. Bloomberg reported that this is Sensex s longest stretch of weekly gains since 2018. Nifty, on the other hand, ended at a weekly loss of 11 points.
Strides receives USFDA approval for Oxybutynin Chloride Tablets
Posted On: 2020-12-18 02:41:57 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.
According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride Tablets USP, 5 mg is approximately US$ 29 Mn. The product will be manufactured at the company s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received
approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.
According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride Tablets USP,
5 mg is approximately US$ 29 Mn. The product will be manufactured at the company s flagship facility
at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
The company has 127 cumulative ANDA filings with USFDA of which 94 ANDAs have been approved